Anti-inflammatory drugs ease anhedonia and depressive symptoms in high-CRP depression, spotlighting CRP-guided treatment and lifestyle strategies while calling for stronger RCTs.
News
Anosognosia drives untreated schizophrenia into homelessness and jail. Here's why civil care fails and how structured treatment can decrease the number of arrests.
Large meta-analysis finds GLP-1 drugs don’t raise depression or suicidality and modestly boost quality of life and eating control in diabetes/obesity.
Review news from the last week in psychiatry.
Leading psychiatric organizations respond to federal push for deprescribing.
Renaming borderline personality disorder fails to address the condition's complexity; keeping the term preserves key clinical meaning, including structural traits and stress-related psychotic symptoms.
Get real-time psychiatry conference highlights with video interviews, session takeaways, and quick clips from APA and psychopharmacology meetings.
Online tool personalizes antidepressant choice in primary care, cutting dropouts and improving 24-week depression and anxiety scores.
New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.
FDA clears MIND1 trial testing NRX-101 plus robotic TMS to curb suicidality in treatment-resistant depression, with military-focused sites.
HHS targets psychiatric overprescribing; expert Joseph F. Goldberg, MD, urges careful deprescribing—stop ineffective medications and replace with evidence-based treatments.
Explore how neuromelanin-sensitive MRI noninvasively tracks long-term dopamine and noradrenaline system changes.
Learn how dual antipsychotics can mask the true cause of high prolactin, and how stepwise switches to aripiprazole or clozapine restore cycles.
New cohort and global data link teen high-potency cannabis use to higher psychosis, bipolar, and suicide risks. Here's what psychiatrists and mental health clinicians should know in the era of legalization.
HHS rolls out a plan to curb psychiatric overprescribing, pushing deprescribing guidance as APA and AFSP urge caution and access to care.
Explore how chatbot brains diverge and compete with human brains.
New analysis ranks lumateperone top for adjunctive MDD symptom relief, with minimal weight gain vs other atypical antipsychotics.
Low soluble α2δ‑1 disrupts brain excitation‑inhibition balance in schizophrenia.
Round on the latest news in psychiatry from the last week.
New data shows stable symptoms when switching from atypical antipsychotics to Cobenfy using cross-titration.
In the wake of the FDA fast-track of psychedelic therapies, we want to hear your clinical pearls for our May theme.
Check out the pipeline updates from April!
The FDA has approved Auvelity, an oral NMDA/sigma-1 therapy, offering a new option to curb Alzheimer disease agitation and ease caregiver burden.
Clinicians explore neuroscience-guided off-label prescribing.
DSM-6 forces psychiatry to choose: sharper science or softer labels. Explore why validity, biomarkers, and hierarchy matter for credibility.
The triple-blinded EPISODE trial with active placebo and 4 dosing regimens yielded mixed results, reflecting the challenge of discerning psilocybin effect and distinguishing between enlightenment and expectation.
New US patent backs Denovo’s ANK3 biomarker guiding DB104 for treatment‑resistant depression, highlighting promising efficacy in selected patients.
Lifestyle medicine pillars help reshape depression and anxiety treatment in psychiatry.
AI video screening spots early tardive dyskinesia signs, prompting clinical follow-up and treatment.
Advertisement
Advertisement